---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-305886"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2022-12-15T23:59:59+00:00"
generated_at: "2026-06-21T04:06:32.279297+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akebia CAO Violetta Cotreau to resign; CFO David Spellman named principal accounting officer

## Summary
- Violetta Cotreau resigns as Chief Accounting Officer, effective Dec 30, 2022, to pursue new career opportunity.
- David A. Spellman, currently CFO, appointed as principal accounting officer effective Dec 30, 2022.
- Spellman has over two decades of biopharma finance experience; previously at Vertex, Intarcia, and Mersana.
- Spellman will continue as CFO and Treasurer in addition to the principal accounting officer role.

## SEC filing metadata
- accession: 0001193125-22-305886
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2022-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/0001193125-22-305886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/d412372d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-305886
- JSON: https://secwatch.observer/filing/0001193125-22-305886.json
- Plain text: https://secwatch.observer/filing/0001193125-22-305886.txt

## Key facts
- Executive change
  Violetta Cotreau resigned as Chief Accounting Officer at Akebia Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Accounting Officer
  source text: On December 14, 2022, Violetta Cotreau, Chief Accounting Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of her intent to resign to pursue a new career opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/0001193125-22-305886-index.htm
- Executive change
  David A. Spellman was appointed as principal accounting officer at Akebia Therapeutics, Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: The Board of Directors of the Company has appointed David A. Spellman, the Company’s Chief Financial Officer, as principal accounting officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/0001193125-22-305886-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.